CAR-T Immunotherapy Colorectal Cancer Research Delivers Remarkable Preclinical Results
Researchers at the Sidney Kimmel Cancer Center at Jefferson Health have demonstrated that CAR-T immunotherapy colorectal cancer treatment successfully eliminates tumors and prevents metastases in mouse models of the disease. Published in Cancer Immunology Research, the study represents the final step of preclinical testing before human clinical trials. According to the Mayo Clinic, colorectal cancer is one of the leading causes of cancer related death in the United States, making this research especially significant.
What Is CAR-T Immunotherapy
CAR-T immunotherapy involves removing a patient’s immune cells, engineering them in a laboratory to target tumor cells specifically, multiplying those cells in large numbers, and then infusing them back into the patient. This targeted burst of engineered immune cells overcomes the immune suppression that tumors use to evade detection and destruction.
For CAR-T immunotherapy colorectal cancer treatment to work, it requires a tumor specific marker called an antigen to serve as a homing beacon for the engineered cells. In colorectal cancer, that antigen is called GUCY2C, first identified as a potential biomarker and therapeutic target by Scott Waldman, MD, PhD, Chair of the Department of Pharmacology and Experimental Therapeutics at Jefferson.
5 Proven Facts About CAR-T Immunotherapy Colorectal Cancer Research
1. The Therapy Eliminated Tumors in Mouse Models
Mice with human colorectal tumors treated with CAR-T immunotherapy colorectal cancer therapy successfully fought tumor cells throughout the observation period. All treated mice survived for 75 days, compared to an average survival of just 30 days in the control group. This outcome confirmed the therapy’s ability to achieve sustained tumor control.
2. The Treatment Prevented Lung Metastases
To replicate advanced stage disease more closely, researchers tested the therapy in a mouse model of colorectal cancer that had already developed lung metastases, a common spread pattern in human patients. Mice treated with CAR-T therapy survived over 100 days with no metastases, while the control group survived an average of just 20 days.
3. The Target Antigen Applies to Multiple High Mortality Cancers
GUCY2C, the antigen targeted by this CAR-T immunotherapy colorectal cancer approach, is shared across several other high mortality cancers including esophageal and pancreatic cancer. As Adam Snook, PhD, Assistant Professor in the Department of Pharmacology and Experimental Therapeutics at Jefferson, noted, approximately 25% of all cancer deaths could potentially be addressed by this therapy.
4. Early Safety Data Shows No Off-Target Effects
Safety is a well known concern in CAR-T therapy research, as lethal autoimmune responses have been observed in other cancer types. Earlier work by Dr. Snook and colleagues used a mouse version of the therapy with potential to react to off-target mouse organs and found no adverse effects, suggesting GUCY2C CAR-T therapy may be both effective and safe.
5. Human Clinical Trials Are the Next Step
The current study represents the last stage of preclinical testing. The next planned step is a Phase I clinical trial in human patients. Karen Knudsen, PhD, Director of the Sidney Kimmel Cancer Center, described the concept of moving CAR-T cell therapy to colorectal cancer as a major breakthrough that could address a significant unmet clinical need.
Why This Advances the Field of Cancer Immunotherapy
CAR-T immunotherapy has already produced cures in patients with certain blood cancers. Extending this approach to solid tumors like colorectal cancer has been a persistent challenge, largely because solid tumors create an immunosuppressive environment that blocks immune cell activity. The GUCY2C targeting strategy used in this research addresses that challenge with a high degree of tumor specificity, offering a promising model for how CAR-T therapy can be adapted to one of the most common and deadly cancers worldwide.
FOMAT conducts Phase I through Phase IV clinical research across a national network of investigator sites throughout the United States. To learn more about active oncology studies, visit our patient active studies page.